Genomics

Dataset Information

0

Epigenetic Reprogramming of mutant RAS-driven Rhabdomyosarcoma via MEK Inhibition

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus Homo sapiens

PROVIDER: GSE85171 | GEO | 2018/04/01

REPOSITORIES: GEO

Json Xml

Similar Datasets

Genomics Epigenetic Reprogramming of mutant RAS-driven Rhabdomyosarcoma via MEK Inhibition
| PRJNA336377 | ENA
Unknown MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma.
| S-EPMC8054766 | biostudies-literature
Unknown MEK inhibition profoundly reprograms myogenic super enhancers in mutant-RAS driven Rhabdomyosarcoma
2018-04-01 | GSE85169 | GEO
Unknown MEK inhibition rewires enhancer landscapes in RAS-driven Rhabdomyosarcoma to unlock a myogenic differentation block
2018-04-01 | GSE85170 | GEO
Unknown Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model.
| S-EPMC5833851 | biostudies-literature
Unknown Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.
| S-EPMC6918830 | biostudies-literature
Unknown Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.
| S-EPMC5628883 | biostudies-literature
Unknown Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition.
| S-EPMC8069437 | biostudies-literature
Unknown SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
| S-EPMC6557854 | biostudies-other
Unknown K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo.
| S-EPMC3432074 | biostudies-literature